Why the study?
Does blood pressure reduction reduce the risk of composite cardiovascular endpoints in patients with hypertension or high cardiovascular risk?
Population
30 trials pooling 221,024 patients with hypertension or composite features of high cardiovascular risk
Comparison
Different BP-lowering agents vs Placebo or active treatments
Design
Meta-analysis
Authors
Loading...
Supports lower BP targets to reduce CV events; confirms dose-response benefit and informs future trial design.
Does blood pressure reduction reduce the risk of composite cardiovascular endpoints in patients with hypertension or high cardiovascular risk?
Blood pressure reduction is significantly associated with a reduced risk of composite cardiovascular endpoints, with a 4.6/2.2 mmHg difference in SBP/DBP required to anticipate a significant difference between treatment groups.
Verdecchia et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: